Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation)

Fulvio Braido, Giovanni Melioli, Mario Cazzola, Leonardo Fabbri, Francesco Blasi, Lorenzo Moretta, Giorgio Walter Canonica

Research output: Contribution to journalArticle

Abstract

Polyvalent mechanical bacterial lysates (PMBLs) have been shown to reduce the number of infectious episodes in patients with recurrent infections of the respiratory tract. Some previous investigations have also shown the effectiveness of PMBLs in reducing exacerbations of chronic obstructive pulmonary disease (COPD). The AIACE study, which was developed according to criteria of evidence-based medicine, evaluated whether the administration of PMBLs to COPD patients, in addition to the recommended treatment, was able to reduce the number of exacerbations by 25%. Two hundred eighty-eight patients with moderate to very severe COPD were recruited and randomly assigned to either placebo or PMBLs. The placebo or PMBLs were administered according to the standard scheme. The primary outcome of the study was not achieved. However, the number of days with fever (21 days per year versus 40.15; p <0.001), the days of hospitalisation (65 days vs 162 days; p <0.001), the interval between the first and second exacerbations (123.89 days vs 70.36; p = 0.03) and the number of days in poor health (109 days/year vs 171 days/year; p <0.001) were significantly better in the PMBL group than in the placebo group. In conclusion, the results of this trials showed that Ismigen, in addition to guideline-suggested treatment, could not significantly reduce the number of exacerbations in the considered population; nevertheless, the secondary outcome results demonstrated potential benefits of this compound for relevant clinical outcomes.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalPulmonary Pharmacology and Therapeutics
Volume33
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Pulmonary diseases
Tongue
Chronic Obstructive Pulmonary Disease
Disease Progression
Placebos
Evidence-Based Medicine
Broncho-Vaxom
Respiratory Tract Infections
Medicine
Hospitalization
Fever
Outcome Assessment (Health Care)
Health
Guidelines
Therapeutics
Population

Keywords

  • Bacterial lysate
  • Chronic obstructive pulmonary disease (COPD)
  • Immune stimulation
  • Polyvalent mechanical bacterial lysate (PMBL)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Cite this

@article{9da853448a604877a596f6a94c5e2366,
title = "Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation)",
abstract = "Polyvalent mechanical bacterial lysates (PMBLs) have been shown to reduce the number of infectious episodes in patients with recurrent infections of the respiratory tract. Some previous investigations have also shown the effectiveness of PMBLs in reducing exacerbations of chronic obstructive pulmonary disease (COPD). The AIACE study, which was developed according to criteria of evidence-based medicine, evaluated whether the administration of PMBLs to COPD patients, in addition to the recommended treatment, was able to reduce the number of exacerbations by 25{\%}. Two hundred eighty-eight patients with moderate to very severe COPD were recruited and randomly assigned to either placebo or PMBLs. The placebo or PMBLs were administered according to the standard scheme. The primary outcome of the study was not achieved. However, the number of days with fever (21 days per year versus 40.15; p <0.001), the days of hospitalisation (65 days vs 162 days; p <0.001), the interval between the first and second exacerbations (123.89 days vs 70.36; p = 0.03) and the number of days in poor health (109 days/year vs 171 days/year; p <0.001) were significantly better in the PMBL group than in the placebo group. In conclusion, the results of this trials showed that Ismigen, in addition to guideline-suggested treatment, could not significantly reduce the number of exacerbations in the considered population; nevertheless, the secondary outcome results demonstrated potential benefits of this compound for relevant clinical outcomes.",
keywords = "Bacterial lysate, Chronic obstructive pulmonary disease (COPD), Immune stimulation, Polyvalent mechanical bacterial lysate (PMBL)",
author = "Fulvio Braido and Giovanni Melioli and Mario Cazzola and Leonardo Fabbri and Francesco Blasi and Lorenzo Moretta and Canonica, {Giorgio Walter}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.pupt.2015.03.006",
language = "English",
volume = "33",
pages = "75--80",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",

}

TY - JOUR

T1 - Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification

T2 - A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation)

AU - Braido, Fulvio

AU - Melioli, Giovanni

AU - Cazzola, Mario

AU - Fabbri, Leonardo

AU - Blasi, Francesco

AU - Moretta, Lorenzo

AU - Canonica, Giorgio Walter

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Polyvalent mechanical bacterial lysates (PMBLs) have been shown to reduce the number of infectious episodes in patients with recurrent infections of the respiratory tract. Some previous investigations have also shown the effectiveness of PMBLs in reducing exacerbations of chronic obstructive pulmonary disease (COPD). The AIACE study, which was developed according to criteria of evidence-based medicine, evaluated whether the administration of PMBLs to COPD patients, in addition to the recommended treatment, was able to reduce the number of exacerbations by 25%. Two hundred eighty-eight patients with moderate to very severe COPD were recruited and randomly assigned to either placebo or PMBLs. The placebo or PMBLs were administered according to the standard scheme. The primary outcome of the study was not achieved. However, the number of days with fever (21 days per year versus 40.15; p <0.001), the days of hospitalisation (65 days vs 162 days; p <0.001), the interval between the first and second exacerbations (123.89 days vs 70.36; p = 0.03) and the number of days in poor health (109 days/year vs 171 days/year; p <0.001) were significantly better in the PMBL group than in the placebo group. In conclusion, the results of this trials showed that Ismigen, in addition to guideline-suggested treatment, could not significantly reduce the number of exacerbations in the considered population; nevertheless, the secondary outcome results demonstrated potential benefits of this compound for relevant clinical outcomes.

AB - Polyvalent mechanical bacterial lysates (PMBLs) have been shown to reduce the number of infectious episodes in patients with recurrent infections of the respiratory tract. Some previous investigations have also shown the effectiveness of PMBLs in reducing exacerbations of chronic obstructive pulmonary disease (COPD). The AIACE study, which was developed according to criteria of evidence-based medicine, evaluated whether the administration of PMBLs to COPD patients, in addition to the recommended treatment, was able to reduce the number of exacerbations by 25%. Two hundred eighty-eight patients with moderate to very severe COPD were recruited and randomly assigned to either placebo or PMBLs. The placebo or PMBLs were administered according to the standard scheme. The primary outcome of the study was not achieved. However, the number of days with fever (21 days per year versus 40.15; p <0.001), the days of hospitalisation (65 days vs 162 days; p <0.001), the interval between the first and second exacerbations (123.89 days vs 70.36; p = 0.03) and the number of days in poor health (109 days/year vs 171 days/year; p <0.001) were significantly better in the PMBL group than in the placebo group. In conclusion, the results of this trials showed that Ismigen, in addition to guideline-suggested treatment, could not significantly reduce the number of exacerbations in the considered population; nevertheless, the secondary outcome results demonstrated potential benefits of this compound for relevant clinical outcomes.

KW - Bacterial lysate

KW - Chronic obstructive pulmonary disease (COPD)

KW - Immune stimulation

KW - Polyvalent mechanical bacterial lysate (PMBL)

UR - http://www.scopus.com/inward/record.url?scp=84938541217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938541217&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2015.03.006

DO - 10.1016/j.pupt.2015.03.006

M3 - Article

C2 - 25951945

AN - SCOPUS:84938541217

VL - 33

SP - 75

EP - 80

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

ER -